id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-0074-0008,FDA,FDA-2014-E-0074,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2016-12-28T05:00:00Z,2016,12,2016-12-28T05:00:00Z,,2016-12-28T15:15:46Z,,0,0,090000648243af7e
FDA-2014-E-0074-0007,FDA,FDA-2014-E-0074,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-12-01T05:00:00Z,2015,12,2015-12-01T05:00:00Z,,2015-12-01T17:32:51Z,,0,0,0900006481d7da9b
FDA-2014-E-0074-0006,FDA,FDA-2014-E-0074,"Determination of Regulatory Review Period for Purposes of Patent
Extension; BOSULIF",Notice,Determinations,2015-05-04T04:00:00Z,2015,5,2015-05-04T04:00:00Z,2015-11-03T04:59:59Z,2015-05-04T14:55:34Z,2015-10333,0,0,0900006481acb35d
FDA-2014-E-0074-0005,FDA,FDA-2014-E-0074,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-04-22T04:00:00Z,2015,4,2015-04-22T04:00:00Z,,2015-04-22T20:14:53Z,,0,0,0900006481ab4ede
FDA-2014-E-0074-0004,FDA,FDA-2014-E-0074,Letter from the U.S. Patent and Trademark Office to FDA,Other,Letter(s),2015-03-24T04:00:00Z,2015,3,2015-03-24T04:00:00Z,,2015-03-24T16:20:33Z,,0,0,0900006481a5f619
FDA-2014-E-0074-0003,FDA,FDA-2014-E-0074,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2014-03-26T04:00:00Z,2014,3,2014-03-26T04:00:00Z,,2014-03-26T15:29:37Z,,0,0,0900006481682d19
FDA-2014-E-0074-0001,FDA,FDA-2014-E-0074,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2014-01-13T05:00:00Z,2014,1,2014-01-13T05:00:00Z,,2014-01-13T15:39:02Z,,0,0,090000648150379d
FDA-2014-E-0074-0002,FDA,FDA-2014-E-0074,Patent Extension from Wyeth Holding Corporation (on behalf of Pfizer Inc.),Other,Application,2014-01-13T05:00:00Z,2014,1,2014-01-13T05:00:00Z,,2014-01-13T15:39:16Z,,0,0,090000648150379c